GlassScriptPhysician profile
Hugh Morgan Ashurst
NPI 1952309965
$5,413.92
in general payments reported to CMS, 2019-2025
38 companies · $37.46 in 2025
The $37.46 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $1,138 · 2021: $889 · 2022: $705 · 2023: $1,120 · 2024: $888 · 2025: $37.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,006 · Education: $39.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,006.17 |
| Education | $39.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $773.76 | 2019-2024 | Spravato, Xarelto |
| Novartis Pharmaceuticals Corporation | $520.23 | 2019-2024 | |
| Pfizer INC. | $459.11 | 2019-2023 | |
| Novo Nordisk INC | $436.31 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $392.51 | 2019-2024 | Zepbound, Mounjaro, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $322.33 | 2019-2024 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $267.06 | 2023-2024 | |
| Abbvie INC. | $246.76 | 2021-2024 | Ubrelvy, Qulipta, Linzess |
| Kowa Pharmaceuticals America, INC. | $199.31 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $198.39 | 2020-2022 | |
| Amgen INC. | $189.08 | 2019-2024 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $184.42 | 2019-2023 | Belsomra, Januvia |
| Glaxosmithkline, LLC. | $167.33 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $164.65 | 2019-2024 | Airsupra, Farxiga |
| Allergan, INC. | $151.32 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugh Ashurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.